Last updated: June 3, 2026
Absorica (isotretinoin) suppliers: manufacturers, labelers, and supply-chain risk factors
Absorica is an oral isotretinoin product (capsules) marketed by Eipharma LLC (US label). Supply is tied to the ability to manufacture pharmaceutical-grade isotretinoin and to execute capsule formulation and packaging under current GMP, with periodic market tightness driven by API availability, regulatory lot disposition, and packaging line capacity.
Who manufactures Absorica (isotretinoin) in the US?
Answer: Absorica is sold in the US under the Eipharma LLC label; the drug product is manufactured by one or more contract manufacturers and the capsule is filled with isotretinoin API. A complete, named list of all current manufacturing and packaging sites requires Orange Book labeler and FDA drug listing cross-references by dosage form and strength.
What does “supplier” mean for Absorica?
For procurement and supply risk, “supplier” typically maps to:
- Labeler (who appears on FDA’s drug product listings and Orange Book)
- Drug substance (API) source (pharmaceutical-grade isotretinoin)
- Drug product manufacturer (capsule filling, blending, finished-goods manufacturing)
- Packaging/labeling sites (secondary packaging and labeling release)
- Distributors/wholesalers (US channel intermediaries)
How to identify the actual manufacturers for Absorica
The industry-standard route is:
- FDA Orange Book: identify listed drug and associated patent set for Absorica, then trace the listed drug’s labeler.
- FDA Structured Product Labeling / SPL: confirm dosage forms and strengths under the labeled product.
- Drug Establishment Registration and Listing (DRER): map labeler to registered finished dosage manufacturers.
- UDS (unsolicited drug listing evidence via company disclosures): identify API suppliers through public procurement and regulatory filings where available.
What is the Orange Book labeler for Absorica?
Answer: Absorica is the listed drug with a specific labeler on the Orange Book; that labeler is the procurement “owner” for regulatory filings and NDA/ANDA transfer signals.
Why labeler matters for sourcing
- Contract manufacturing can rotate without changing labeler.
- Patent litigation and exclusivity events track the NDA holder/labeler and listed drug.
- Wholesale sourcing reliability often depends on which contract manufacturer currently produces release-ready lots.
Which companies supply isotretinoin API used in Absorica?
Answer: Absorica’s supply chain depends on pharmaceutical-grade isotretinoin API production, but named API suppliers cannot be stated without a product-specific disclosure list tied to the currently marketed lots.
API supply constraints that drive shortages
- Limited number of qualified isotretinoin producers globally
- Tight GMP capacity for low-dose/high-potency capsule filling lines
- Regulatory batch release and stability testing that lengthen lead times
- Lot-by-lot variability in API impurity profiles that can force rejections or relabeling actions
How are Absorica capsules made and where do manufacturing bottlenecks occur?
Answer: Bottlenecks generally occur at three steps: API release, capsule filling, and packaging line throughput.
Capsule manufacturing bottlenecks
- Precision weighing and blending consistency for a highly potent teratogen
- Control of moisture and particle size distribution during blending/filling
- Finished-goods stability and dissolution compliance for the marketed capsule strengths
- Serialization/labeling line capacity for REMS-related packaging workflows
What is the FDA status of Absorica that affects suppliers?
Answer: Absorica is subject to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) requirements because it contains isotretinoin. This does not change the manufacturer count directly, but it influences distribution, allocation, and distribution authorization processes.
What suppliers must support under iPLEDGE
- Lot-controlled distribution workflows
- REMS-compliant packaging and labeling processes
- Accurate product identification for dispensing networks
Does Absorica have multiple manufacturers or single-source risk?
Answer: Absorica distribution reflects ongoing capacity management, but the exact count and names of manufacturing sites depend on the currently marketed NDA manufacturing arrangements.
How to evaluate single-source risk
- Compare DRER registrations for the labeler over time
- Review NDA supplements for manufacturing site changes
- Track batch lot reports through pharmacy wholesaler pipelines
- Watch for public signals in FDA enforcement actions, recall announcements, or GMP inspection outcomes affecting registered sites
What generic or authorized alternatives can substitute for Absorica supply?
Answer: Generic isotretinoin capsule products can substitute at the therapeutic level, but interchangeability depends on:
- Strength equivalence
- Bioavailability profile
- Formulation and excipient differences
- iPLEDGE dispensing practices and pharmacy formularies
Supply planning implication
If Absorica supply tightens, procurement usually shifts to:
- Other isotretinoin capsule brands/generics with active supply
- Alternate dosage strengths within the same REMS program workflow
- Short-term purchasing from wholesalers with diversified inventory depth
How to map Absorica “suppliers” for procurement and diligence
Answer: Use a three-layer procurement map: labeler, finished-goods manufacturer, and API source.
Procurement diligence checklist (actionable)
- Confirm labeler on the Orange Book listing for the specific Absorica strength.
- Pull DRER registrations to identify registered finished-dosage manufacturing and packaging sites.
- Confirm GMP status of those sites via public inspection records.
- Validate that distributors can support iPLEDGE-compliant lot-controlled distribution.
- Require CoA lot traceability for isotretinoin potency, impurities, residual solvents, and stability program compliance.
Key Takeaways
- “Suppliers for Absorica” in practice are: the US labeler, contract finished-goods manufacturers, and the pharmaceutical isotretinoin API supply chain.
- Absorica availability is governed by GMP release capacity, capsule filling and packaging throughput, and iPLEDGE-compliant distribution workflows.
- Named manufacturing and API suppliers must be derived from FDA Orange Book labeler mapping, SPL/DRER records, and lot-specific sourcing evidence because contract manufacturing can change while the labeler stays constant.
FAQs
- How do I confirm the current manufacturer of Absorica capsules for a specific strength and lot?
- What iPLEDGE/REMS constraints affect Absorica distribution when supply tightens?
- What procurement indicators signal an isotretinoin API shortage that could impact Absorica?
- How do generic isotretinoin capsule brands differ in supply reliability versus Absorica?
- What regulatory steps occur when Absorica changes manufacturing sites (GMP transfers/supplements)?
References
- FDA Orange Book. “Absorica” (listed drug entry). US Food and Drug Administration.
- FDA iPLEDGE REMS. US Food and Drug Administration.
- FDA DRER (Drug Registration and Establishment Registration). US Food and Drug Administration.
